South and Central America Injectable Drug Delivery Market Analysis and Forecast by Size, Share, Growth, Trends 2031

The South and Central America Injectable Drug Delivery Market size is expected to reach US$ 2,240.7 Million by 2031 from US$ 1,441.1 Million in 2024. The market is estimated to record a CAGR of 6.6% from 2025 to 2031.

Executive Summary and South and Central America Injectable Drug Delivery Market Analysis:

The South and Central America injectable drug delivery market is segmented into Brazil, Argentina, and the Rest of South and Central America. The market is driven by increasing non-communicable diseases (NCDs) and supported by public health systems. The Pan American Health Organization (PAHO) reports 112 million adults with diabetes across the Americas in 2023, with South and Central subregions accounting for ~32 million, prevalence at 13.1%, tripling since 1990 due to aging and obesity. Treatment coverage lags, with only 58% of those aged 30+ receiving care, including insulin injections essential for type 1 diabetes (10% of cases) and advanced type 2.

Injectables are the cornerstone for NCD management; PAHO notes diabetes causes 244,000 deaths yearly, often mitigated by subsidized insulin pens in Brazil's SUS program, serving 20 million diabetics. PAHO's 2024 data shows 85% DTP3 coverage via injectables, with HPV shots preventing 90,000 cervical cancers annually in the region. Denosumab injections for osteoporosis in postmenopausal women address 20 million at-risk individuals in Argentina. The regional pacts, such as MERCOSUR, enhance procurement. Biosimilar adoption, at 40% market penetration in Chile, lowers costs by 30%. With 650 million inhabitants, injectables drive 50% of pharma volume, pivotal for universal coverage goals in the near future.

South & Central America Injectable Drug Delivery Market: Strategic Insights

South and Central America Injectable Drug Delivery Market Segmentation Analysis:

• By Device Type, the South and Central America Injectable Drug Delivery Market is segmented into Conventional Drug Delivery Devices and Advanced Drug Delivery Devices. The Conventional Drug Delivery Devices segment dominated the market in 2024.
• By Advanced Drug Delivery Devices By Device Type, the South and Central America Injectable Drug Delivery Market is segmented into Prefilled Syringes, Pen Injectors, Auto-Injectors, Needle-Free Injectors, Wearable Injectors, and Other Advanced Types. The Prefilled Syringes segment dominated the market in 2024.
• By Formulation, the South and Central America Injectable Drug Delivery Market is segmented into Conventional Drug Delivery, Novel Drug Delivery, and Long Acting Injectable Formulations. The Conventional Drug Delivery segment dominated the market in 2024.
• By Conventional Drug Delivery By Formulation, the South and Central America Injectable Drug Delivery Market is segmented into Solutions, Reconstituted or Lyophilized formulations, Suspensions, and Emulsion. The Solutions segment dominated the market in 2024.
• By Novel Drug Delivery By Formulation, the South and Central America Injectable Drug Delivery Market is segmented into Colloidal Dispersion, Microparticles, and Other Novel Drug Delivery. The Colloidal Dispersion segment dominated the market in 2024.
• By Formulation Packaging, the South and Central America Injectable Drug Delivery Market is segmented into Ampoules, Vials, Cartridges, and Bottles. The Vials segment dominated the market in 2024.
• By Therapeutic Application, the South and Central America Injectable Drug Delivery Market is segmented into Diabetes, Oncology, Auto-Immune Disorders, Cardiovascular Diseases, Infectious Diseases, Pain Management, and Other Therapeutic Application. The Diabetes segment dominated the market in 2024.
• By Route of Administration, the South and Central America Injectable Drug Delivery Market is segmented into Sub-cutaneous, Intramuscular, Intravenous, and Other Route of Administration. The Sub-cutaneous segment dominated the market in 2024.
• By Usability, the South and Central America Injectable Drug Delivery Market is segmented into Disposable Injectors and Re-usable Injectors. The Disposable Injectors segment dominated the market in 2024.
• By End User, the South and Central America Injectable Drug Delivery Market is segmented into Pharmaceutical and Biopharma Companies and CMOs and CDMOs. The Pharmaceutical and Biopharma Companies segment dominated the market in 2024.

South & Central America Injectable Drug Delivery Market Players Density: Understanding Its Impact on Business Dynamics

The South & Central America Injectable Drug Delivery Market is growing rapidly, driven by increasing end-user demand due to factors such as evolving consumer preferences, technological advancements, and greater awareness of the product's benefits. As demand rises, businesses are expanding their offerings, innovating to meet consumer needs, and capitalizing on emerging trends, which further fuels market growth.

South and Central America Injectable Drug Delivery Market Outlook

The integration of artificial intelligence (AI) in injectable drug delivery systems is poised to transform personalized medicine by enabling real-time dosing adjustments, predictive adherence monitoring, and optimized formulation designs, reducing adverse events and enhancing therapeutic efficacy for chronic conditions. AI algorithms, embedded in smart autoinjectors and wearable sensors, will analyze patient-specific data such as glucose levels or inflammation markers to automate insulin or biologic injections, minimizing errors that currently affect up to 20% of self-administered doses. NIH-funded prototypes such as AI-enhanced insulin pens, tested in 2025 clinical trials, use machine learning to predict hypoglycemic episodes and adjust delivery volumes, demonstrating a 35% improvement in time-in-range for type 1 diabetes patients compared to standard devices. This trend builds on AI applications in drug discovery, where convolutional neural networks have accelerated nanomedicine formulation by 50% through virtual screening of lipid compositions for sustained-release injectables. Projections by the WHO indicate that noncommunicable diseases, including diabetes, affected 537 million adults in 2021 and are expected to reach 783 million by 2045, which will drive demand for such innovations, as injectable therapies remain central to management yet face adherence barriers in 50% of cases. Emerging nano bio-robots, powered by AI for targeted delivery, could enable site-specific injections for oncology, reducing systemic toxicity by 40% in preclinical models. Challenges such as data privacy will necessitate robust frameworks, but collaborations between the FDA and EMA for AI validation guidelines, as outlined in 2025 regulatory updates, pave the way. By 2031, this trend could integrate with IoT for cloud-based analytics, fostering equitable access in low-resource settings through low-cost AI chips, averting millions of complications, and aligning with global health equity goals.

South and Central America Injectable Drug Delivery Market Country Insights

By country, the South and Central America Injectable Drug Delivery Market is segmented into Brazil, Argentina, and the Rest of South and Central America. Brazil held the largest share in 2024.

With diabetes prevalence rising from 6.2% in 2013 to 10.6 in 2024, affecting over 16 million adults, insulin usage stands at 69.3% among diagnosed patients, often via pen devices for better adherence. The Unified Health System (SUS) dispenses insulin free-of-charge, with annual treatment costs averaging US$ 1,216 per patient, 92% of which covers injectables and monitoring supplies. Medication access improved to reduce complications such as neuropathy.

The National Immunization Program achieved 76.96% mean coverage pre-pandemic, though declining to 69.4% by 2021 due to hesitancy, with recovery in BCG (birth dose) and polio to positive trends by 2024. Brazil's 2025 dengue vaccine rollout, a single-dose injectable from Butantan Institute, targets 80 million at-risk individuals, boosting coverage amid 2024's 6 million cases. For HIV, long-acting injectables such as cabotegravir enable biannual dosing, aligning with 71% regional treatment coverage. Reproductive health sees 4.5% injectable contraceptive use, rising among low-income groups post-COVID, where sales surged 47% for combined injectables during lockdowns for reliable delivery. Innovations such as Uniject pre-filled syringes enhance maternal oxytocin administration, reducing postpartum hemorrhage by 30% in trials. The SUS integration ensures equity, positioning Brazil as a regional leader in scalable injectables.

South and Central America Injectable Drug Delivery Market Company Profiles

Some of the key players operating in the market include B Braun SE, Terumo Corp, Cardinal Health Inc, Phillips-Medisize, Nipro Corp, Gerresheimer AG, West Pharmaceutical Services Inc, Schott AG, Becton Dickinson and Co, Kindeva Drug Delivery LP

These players are adopting various strategies such as expansion, product innovation, and mergers and acquisitions to provide innovative products to their consumers and increase their market share.

South and Central America Injectable Drug Delivery Market Research Methodology

The following methodology has been followed for the collection and analysis of data presented in this report:

Secondary Research

The research process begins with comprehensive secondary research, utilizing internal and external sources to gather qualitative and quantitative data for each market. Commonly referenced secondary research sources include, but are not limited to:

• Company websites, annual reports, financial statements, broker analyses, and investor presentations
• Industry trade journals and other relevant publications
• Government documents, statistical databases, and market reports
• News articles, press releases, and webcasts specific to companies operating in the market

Note: All financial data included in the Company Profiles section has been standardized to US$. For companies reporting in other currencies, figures have been converted to US$ using the relevant exchange rates for the corresponding year.

Primary Research

The Insight Partners conducts a significant number of primary interviews each year with industry stakeholders and experts to validate its data analysis and gain valuable insights. These research interviews are designed to:

• Validate and refine findings from secondary research
• Enhance the expertise and market understanding of the analysis team
• Gain insights into market size, trends, growth patterns, competitive dynamics, and future prospects

Primary research is conducted via email interactions and telephone interviews, encompassing various markets, categories, segments, and sub-segments across different regions. Participants typically include:

• Industry stakeholders: Vice Presidents, Business Development Managers, Market Intelligence Managers, and National Sales Managers
• External experts: Valuation specialists, research analysts, and key opinion leaders with industry-specific expertise